Koninklijke Philips N.V. (PHG - Free Report) reported third-quarter 2022 adjusted earnings of €0.25 per share, down 37.5% year over year.
Sales increased 3.7% on a year-over-year basis to €4.31 billion. Comparable sales (including adjustments for consolidation charges & currency effects) decreased 5% year over year, primarily due to headwinds caused by global supply chain challenges, COVID lockdowns in China and the Russia-Ukraine war.
Comparable sales in the Personal Health businesses witnessed mid-single-digit increases on a year-over-year basis. The Diagnosis & Treatment and Connected Care businesses witnessed a double-digit and low-single-digit decline, respectively.
Philips’ comparable order intake decreased 6% year over year in the reported quarter. Diagnosis & Treatment businesses witnessed low-single-digit growth, while the Connected Care business witnessed a double-digit decline.
Sales decreased 4% on a comparable basis in growth geographies. Sales in mature geographies were down 6% year over year on a comparable basis.
Philips’ shares were down more than 1.01% following the third-quarter 2022 results. Markedly, Philips’ shares have declined 65% year to date compared with the Zacks Medical-Products industry’s decline of 47.1%.
Segmental Update
Diagnosis & Treatment revenues increased 6% from the year-ago quarter to €2.29 billion. Comparable sales declined 2% year over year.
Image-Guided Therapy witnessed low-single-digit growth in the reported quarter. However, Ultrasound and Diagnostic Imaging revenues declined due to specific electronic component shortages.
Connected Care business revenues declined 6% year over year to €982 million. Comparable sales decreased 13%, primarily due to the impact of operational and supply chain challenges.
Personal Health’s comparable sales were up 4%, with a high-single-digit decline in Oral Healthcare and Mother & Child Care and low-single-digit growth in Personal Care.
Other segment sales amounted to €135 million, down €24 million on a year-over-year basis.
Operating Details
Gross margin contracted 730 basis points (bps) on a year-over-year basis to 40.1% in the reported quarter.
General & administrative expenses, as a percentage of sales, increased 10 bps on a year-over-year basis to 4.1%. Moreover, selling expenses increased 170 bps to 26.8%. Research & development expenses also increased 380 bps to 14.3%.
Restructuring, acquisition-related and other charges amounted to €303 million compared with €87 million in the year-ago quarter.
Philips’ adjusted earnings before interest, taxes and amortization (“EBITA”) — the company’s preferred measure of operational performance — declined 59.2% year over year to €209 million.
Diagnosis & Treatment’s EBITA margins contracted 360 bps on a year-over-year basis to 13.4%.
Connected Care’s adjusted EBITA loss was €93 million against the year-ago quarter’s adjusted EBITA of €67 million.
Personal Health’s adjusted EBITA margins contracted 150 bps on a year-over-year basis to 14.1%.
Balance Sheet
As of Sep 30, 2022, Philips’ cash and cash equivalents were €776 million and total debt was €8.31 billion. This compares with cash and cash equivalents of €1.26 billion and total debt of €8 billion as of Jun 30, 2022.
Operating cash outflow was €180 million against operating cash flow of €256 million.
Guidance
Philips expects fourth-quarter 2022 comparable sales to decline mid-single-digit. Adjusted EBITA margin is expected to be in the high-single to double-digit range.
Zacks Rank and Stocks to Consider
Phillips currently has a Zacks Rank #5 (Strong Sell).
AMN Healthcare (AMN - Free Report) , Accuray (ARAY - Free Report) and Molina Healthcare (MOH - Free Report) are some better-ranked stocks worth considering in the same industry. While AMN Healthcare sports a Zacks Rank #1 (Strong Buy), Accuray and Molina carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare and Accuray are set to report their quarterly results on Nov 3 and 2, respectively. Molina is expected to report its quarterly results on Oct 26.
On a year-to-date basis, AMN and ARAY have lost 3.4% and 57%, respectively. However, shares of Molina have improved 14.6% over the same timeframe.
Free Report: Must-See Energy Stocks for 2023
Record profits at oil companies can mean big gains for you. With soaring demand and elevated prices, oil stocks could be top performers by far in 2023. Zacks has released a special report revealing the 4 oil stocks experts believe will deliver the biggest gains. (You’ll never guess Stock #2!)
Download Oil Market on Fire today, absolutely free.
Koninklijke Philips N.V. (PHG - Free Report) reported third-quarter 2022 adjusted earnings of €0.25 per share, down 37.5% year over year.
Sales increased 3.7% on a year-over-year basis to €4.31 billion. Comparable sales (including adjustments for consolidation charges & currency effects) decreased 5% year over year, primarily due to headwinds caused by global supply chain challenges, COVID lockdowns in China and the Russia-Ukraine war.
Comparable sales in the Personal Health businesses witnessed mid-single-digit increases on a year-over-year basis. The Diagnosis & Treatment and Connected Care businesses witnessed a double-digit and low-single-digit decline, respectively.
Philips’ comparable order intake decreased 6% year over year in the reported quarter. Diagnosis & Treatment businesses witnessed low-single-digit growth, while the Connected Care business witnessed a double-digit decline.
Sales decreased 4% on a comparable basis in growth geographies. Sales in mature geographies were down 6% year over year on a comparable basis.
Philips’ shares were down more than 1.01% following the third-quarter 2022 results. Markedly, Philips’ shares have declined 65% year to date compared with the Zacks Medical-Products industry’s decline of 47.1%.
Segmental Update
Diagnosis & Treatment revenues increased 6% from the year-ago quarter to €2.29 billion. Comparable sales declined 2% year over year.
Image-Guided Therapy witnessed low-single-digit growth in the reported quarter. However, Ultrasound and Diagnostic Imaging revenues declined due to specific electronic component shortages.
Connected Care business revenues declined 6% year over year to €982 million. Comparable sales decreased 13%, primarily due to the impact of operational and supply chain challenges.
Personal Health’s comparable sales were up 4%, with a high-single-digit decline in Oral Healthcare and Mother & Child Care and low-single-digit growth in Personal Care.
Other segment sales amounted to €135 million, down €24 million on a year-over-year basis.
Operating Details
Gross margin contracted 730 basis points (bps) on a year-over-year basis to 40.1% in the reported quarter.
General & administrative expenses, as a percentage of sales, increased 10 bps on a year-over-year basis to 4.1%. Moreover, selling expenses increased 170 bps to 26.8%. Research & development expenses also increased 380 bps to 14.3%.
Restructuring, acquisition-related and other charges amounted to €303 million compared with €87 million in the year-ago quarter.
Philips’ adjusted earnings before interest, taxes and amortization (“EBITA”) — the company’s preferred measure of operational performance — declined 59.2% year over year to €209 million.
Diagnosis & Treatment’s EBITA margins contracted 360 bps on a year-over-year basis to 13.4%.
Connected Care’s adjusted EBITA loss was €93 million against the year-ago quarter’s adjusted EBITA of €67 million.
Personal Health’s adjusted EBITA margins contracted 150 bps on a year-over-year basis to 14.1%.
Balance Sheet
As of Sep 30, 2022, Philips’ cash and cash equivalents were €776 million and total debt was €8.31 billion. This compares with cash and cash equivalents of €1.26 billion and total debt of €8 billion as of Jun 30, 2022.
Operating cash outflow was €180 million against operating cash flow of €256 million.
Guidance
Philips expects fourth-quarter 2022 comparable sales to decline mid-single-digit. Adjusted EBITA margin is expected to be in the high-single to double-digit range.
Zacks Rank and Stocks to Consider
Phillips currently has a Zacks Rank #5 (Strong Sell).
AMN Healthcare (AMN - Free Report) , Accuray (ARAY - Free Report) and Molina Healthcare (MOH - Free Report) are some better-ranked stocks worth considering in the same industry. While AMN Healthcare sports a Zacks Rank #1 (Strong Buy), Accuray and Molina carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare and Accuray are set to report their quarterly results on Nov 3 and 2, respectively. Molina is expected to report its quarterly results on Oct 26.
On a year-to-date basis, AMN and ARAY have lost 3.4% and 57%, respectively. However, shares of Molina have improved 14.6% over the same timeframe.
Free Report: Must-See Energy Stocks for 2023
Record profits at oil companies can mean big gains for you. With soaring demand and elevated prices, oil stocks could be top performers by far in 2023. Zacks has released a special report revealing the 4 oil stocks experts believe will deliver the biggest gains. (You’ll never guess Stock #2!)
Download Oil Market on Fire today, absolutely free.
Get the latest research report on ARAY - FREE
Get the latest research report on PHG - FREE
Get the latest research report on MOH - FREE
Get the latest research report on AMN - FREE